Cubist Daptomycin VRE Pivotal Trial May Include Synercid Comparison
Executive Summary
Pivotal trials for Cubist's daptomycin antibiotic against vancomycin-resistant Enterococcus are expected to include a comparative arm with Rhone-Poulenc Rorer's Synercid (quinupristin/dalfopristin).
You may also be interested in...
Rhone-Poulenc Rorer Targets September Launch For Synercid In U.K.
Rhone-Poulenc Rorer's injectable streptogramin antibiotic Synercid (quinupristin/dalfopristin) is expected to be launched in the U.K. by October, following approval by the Medicines Control Agency on July 29.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011